Autologous Haemopoietic Stem-Cell Transplantation for Aggressive Multiple Sclerosis

Ontaneda D , Fox RJ , Chataway J . Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol 2015; 14: 208–23.

NHS England. Clinical commissioning policy: Disease modifying therapies for patients with Multiple Sclerosis May 2014. NHS England/D04/P/b.

MS Society. Time to Act - a consensus on early treatment. 2015.

Mancardi G , Saccardi R . Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008; 7: 626–36.

Burt RK , Balabanov R , Han X . Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA 2015; 313: 275–84.

Nash RA , Hutton GJ , Racke MK . High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol 2015; 72: 159–69.

Coles AJ , Wing MG , Molyneux P . Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296–304.

Krasulova E , Trneny M , Kozak T . High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 2010; 16: 685–93.

Coles AJ , Boyko AN , Cohen JA . Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I) London: ECTRIMS; 2016.

Confavreux C , Vukusic S , Moreau T . Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430–8.

Fisher E , Rudick RA , Simon JH . Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412–20.

Chard DT , Brex PA , Ciccarelli 0 . The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry 2003; 74: 1551–4.

Scalfari A , Neuhaus A , Degenhardt A . The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010; 133(Pt 7):1914–29.

Confavreux C , Vukusic S . Age at disability milestones in multiple sclerosis. Brain 2006; 129(Pt 3):595–605.

Leray E , Yaouanq J , Le Page E . Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133(Pt 7):1900–13.

Scalfari A , Neuhaus A , Daumer M . Age and disability accumulation in multiple sclerosis. Neurology 2011; 77: 1246–52.

Pittock SJ , Mayr WT , McClelland RL . Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004; 62: 601–6.